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To the Editor:
We thank Phillipe et al. for creating this opportunity to
clarify the methods of busulfan concentration determination
and area under the curve (AUC) calculation used in our
evaluation of the performance of pediatric guidelines for
initial busulfan dosing [1]. As stated in our article, plasma
busulfan concentrations were assayed using gas chroma-
tography [2,3] by the Department of Laboratory Medicine at
The Hospital for Sick Children. Our laboratory participates in
external proﬁciency testing organized by Otsuka Canada
Pharmaceutical Inc. (St. Laurent, Quebec, Canada), and the
results are reviewed by the hospital’s Therapeutic Drug
Monitoring Committee. The between-day coefﬁcient of
variation of this assay 3.8% to 6.8%, and our performance in
external proﬁciency testing is very good.
The stability of busulfan in plasma is affected by tem-
perature. When stored at room temperature or at 4C for
24 hours, plasma busulfan concentrations drop by 25% and
<5%, respectively [4]. Frozen samples are very stable. At our
center blood samples are sent to our laboratory as soon as
they are drawnwhere they are immediately separated under
refrigeration and frozen at20C until assayed. For the short
time that blood samples are in transit between the patient
and the laboratory, they are not kept on ice. Patient samples
are assayed within 12 hours of being drawn. We do not
believe that our handling procedures lead to signiﬁcant
degradation of busulfan content.
All samples for busulfan determination were obtained af-
ter completion of infusion of the ﬁrst busulfan dose and before
administration of the second busulfan dose. However, our
practice with respect to the number and timing of samples
obtained for each patient changed when we adopted a vali-
dated limited sampling strategy for routine clinical use [5].
Thus, our study cohort of 111 children represents 2 situations:
 Patients who had a sufﬁcient number of blood samples
available to permit conﬁdent application of a ﬁrst
order, 1-compartment model for i.v. infusions (model 2,
Phoenix WinNonLin 6.3; Pharsight, St. Louis, MO). Of
these, 50 received busulfan every 6 hours and had 7
blood samples drawn at 2 (at the end of the 2-hour
infusion), 2.25, 2.5, 3, 4, 5, and 6 (just before next
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Another 25 patients received busulfan every 24 hours
and had 6 blood samples drawn at 3 (at the end of the
3-hour infusion), 3.25, 4, 5, 6, and 8 hours after the start
of the ﬁrst busulfan infusion.
 Patients who did not have a sufﬁcient number of blood
samples available to permit traditional 1-compartment
modeling. The validated limited sampling strategy [5]
(3 samples per patient; blood samples at 4, 5, and 6
hours after the start of the 2-hour infusion) was used to
estimate busulfan AUC in the remaining 36 patients, all
of whom received busulfan every 6 hours. Because
excellent agreement between AUCs derived from
our limited sampling strategy and 1-compartment
modeling has been demonstrated, we elected to
include patients who had busulfan AUC calculated
using either method in our study.
All the pediatric busulfan dosing guidelines evaluated in
our study aimed to achieve a target AUC after administra-
tion of the ﬁrst i.v. busulfan dose. We calculated busulfan
AUC from the start of the infusion of the ﬁrst busulfan dose
(time 0) to inﬁnity. This AUC does not reﬂect steady state
but does reﬂect the entire AUC for which the dose admin-
istered is responsible. Assessment at steady state is not
necessary to make busulfan dose adjustments or to compare
the AUC values that would arise if different initial busulfan
doses were given to the same patient. Indeed, this is the
principle that underpins the concept of busulfan test doses
and dose adjustment [6,7]. We did not use AUC0-6 in our
study.
Finally, we are pleased that Phillipe et al. agree that the
variability in AUC achievement we describe across busulfan
dosing guidelines is likely correct. It is also our hope that
clinicians ﬁnd our results helpful when developing standards
of care.
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